atomoxetine hydrochloride has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrol, A; Calhoun, VD; Dammer, EB; Duong, DM; Edland, SD; Fagan, AM; Galasko, D; Gámez Tansey, M; Goldstein, DS; Goldstein, FC; Hajjar, I; Hales, CM; Hanfelt, J; Higginbotham, L; Hu, WT; Lah, JJ; Levey, AI; Qiu, D; Seyfried, NT; Weinshenker, D; Wingo, TS; Zhao, L | 1 |
| Baker, KD; Feldman, PD; Mohs, RC; Porsteinsson, AP; Shiovitz, TM; Tariot, PN | 1 |
2 trial(s) available for atomoxetine hydrochloride and Alzheimer Disease
| Article | Year |
|---|---|
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
Topics: Adolescent; Adult; Alzheimer Disease; Amyloid beta-Peptides; Antigens, Neoplasm; Atomoxetine Hydrochloride; Biomarkers; Cell Adhesion Molecules; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Method; Drug Repositioning; Humans; Inflammation; Middle Aged; Neuroprotection; Norepinephrine; tau Proteins | 2022 |
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Alzheimer Disease; Atomoxetine Hydrochloride; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Propylamines; Treatment Outcome | 2009 |